VANDA PHARMACEUTICALS INC (VNDA)       10.735  +0.24 (+2.34%)

10.735  +0.24 (+2.34%)

US9216591084 - Common Stock

VANDA PHARMACEUTICALS INC10.735

NASDAQ:VNDA (11/30/2022, 1:13:08 PM)+0.24 (+2.34%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 11-02 2022-11-02/amc Earnings (Next) 02-21 2023-02-21
Ins Owners 3.64% Inst Owners 97.71%
Market Cap 607.49M Shares 56.59M
PE 89.46 Fwd PE 40.48
Dividend Yield N/A Analysts 43.33
IPO 04-12 2006-04-12

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

VNDA Daily chart

Company Profile

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The company is headquartered in Washington, Washington Dc and currently employs 278 full-time employees. The company went IPO on 2006-04-12. Vanda’s commercial portfolio comprised of two products, HETLIOZ and nighttime sleep disturbances, and Fanapt for the treatment of schizophrenia. In addition, the Company has a range of drugs in development, including HETLIOZ (tasimelteon) for the treatment of jet lag disorder, delayed sleep phase disorder (DSPD), symptoms of autism spectrum disorder and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar disorder and Parkinson s disease psychosis and a long acting injectable formulation for the treatment of schizophrenia; Tradipitant (VLY-686) for the treatment of gastroparesis, motion sickness, atopic dermatitis, and Covid-19 pneumonia, and VTR-297 for the treatment of hematologic malignancies and with potential use as a treatment for several oncology indications.

Company Info

VANDA PHARMACEUTICALS INC

Suite 300E, 2200 Pennsylvania Ave Nw

WASHINGTON WASHINGTON DC 20037

P: 12027343400.0

CEO: Mihael H. Polymeropoulos

Employees: 278

Website: https://www.vandapharma.com/

VNDA News

News Image22 days ago - BusinessInsiderVanda Pharmaceuticals Announces Participation at November 2022 Investor Conferences

WASHINGTON, Nov. 8, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in th...

News Image22 days ago - Vanda Pharmaceuticals Inc.Vanda Pharmaceuticals Announces Participation at November 2022 Investor Conferences

/PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the following upcoming investor...

News Imagea month ago - BusinessInsiderVanda Pharmaceuticals Reports Third Quarter 2022 Financial Results

Q3 2022 total revenues were $65.3 millionTotal revenues in the first nine months of 2022 were $189.9 millionVanda provides update on pipeline adva...

News Imagea month ago - BusinessInsiderVanda Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022

Conference Call and Webcast to FollowWASHINGTON, Oct. 26, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced i...

News Imagea month ago - Vanda Pharmaceuticals Inc.Vanda Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022

/PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2022 on Wednesday, November 2,...

News Image2 months ago - Vanda Pharmaceuticals Inc.Vanda Pharmaceuticals and OliPass Announce Strategic Partnership to Develop Antisense Oligonucleotide Therapeutics

/PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and OliPass Corporation (OliPass) (KOSDAQ: 24460) today announced that they have entered into...

VNDA Twits

Here you can normally see the latest stock twits on VNDA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example